134 related articles for article (PubMed ID: 37619265)
1. Preparation of an Ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy.
Zhang H; Sun J; Zhang Y; Zhang Z; Wang X; Liu Z; Zhang X; Tang Z; Chen X
Biomaterials; 2023 Oct; 301():122285. PubMed ID: 37619265
[TBL] [Abstract][Full Text] [Related]
2. An MMAE-loaded PDL1 active targeting nanomedicine for the precision treatment of colon cancer.
Zhang Z; Zhang H; Cui L; Wang X; Wang D; Liu Z; Zhang X; Tang Z
Biomater Sci; 2023 Jul; 11(15):5195-5204. PubMed ID: 37337707
[TBL] [Abstract][Full Text] [Related]
3. Organic-Solvent-Free "Lego-Like" Modular Preparation of Fab-Nondestructive Antibody-Drug Conjugates with Ultrahigh Drug-to-Antibody Ratio.
Liu Z; Zhang H; Sun J; Zheng M; Cui L; Zhang Y; Cheng J; Tang Z; Chen X
Adv Mater; 2023 Nov; 35(46):e2300377. PubMed ID: 37532247
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates.
Yao Y; Yu L; Su X; Wang Y; Li W; Wu Y; Cheng X; Zhang H; Wei X; Chen H; Zhang R; Gou L; Chen X; Xie Y; Zhang B; Zhang Y; Yang J; Wei Y
J Control Release; 2015 Dec; 220(Pt A):5-17. PubMed ID: 26439663
[TBL] [Abstract][Full Text] [Related]
5. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Assisted Delivery of a Peptide-Drug Conjugate for Targeted Cancer Therapy.
Kim H; Hwang D; Choi M; Lee S; Kang S; Lee Y; Kim S; Chung J; Jon S
Mol Pharm; 2019 Jan; 16(1):165-172. PubMed ID: 30521347
[TBL] [Abstract][Full Text] [Related]
7. Anticancer activity of polymeric nanoparticles containing linoleic acid-SN38 (LA-SN38) conjugate in a murine model of colorectal cancer.
Cheng G; Zhang X; Chen Y; Lee RJ; Wang J; Yao J; Zhang Y; Zhang C; Wang K; Yu B
Colloids Surf B Biointerfaces; 2019 Sep; 181():822-829. PubMed ID: 31247407
[TBL] [Abstract][Full Text] [Related]
8. Injectable Reactive Oxygen Species-Responsive SN38 Prodrug Scaffold with Checkpoint Inhibitors for Combined Chemoimmunotherapy.
Gong Y; Chen M; Tan Y; Shen J; Jin Q; Deng W; Sun J; Wang C; Liu Z; Chen Q
ACS Appl Mater Interfaces; 2020 Nov; 12(45):50248-50259. PubMed ID: 33135879
[TBL] [Abstract][Full Text] [Related]
9. A glyco-engineering approach for site-specific conjugation to Fab glycans.
Jaramillo ML; Sulea T; Durocher Y; Acchione M; Schur MJ; Robotham A; Kelly JF; Goneau MF; Robert A; Cepero-Donates Y; Gilbert M
MAbs; 2023; 15(1):2149057. PubMed ID: 36447399
[TBL] [Abstract][Full Text] [Related]
10. Photoconjugation of an Fc-Specific Peptide Enables Efficient DAR 2 Antibody-Drug Conjugate Formation.
Lee T; Kim JH; Kwon SJ; Park SH; Kim J; Kang HJ; Chung SJ
Org Lett; 2020 Nov; 22(21):8419-8423. PubMed ID: 33074682
[TBL] [Abstract][Full Text] [Related]
11. Site-Specific Antibody-Drug Conjugates in Triple Variable Domain Fab Format.
Hwang D; Rader C
Biomolecules; 2020 May; 10(5):. PubMed ID: 32422893
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticulate delivery of irinotecan active metabolite (SN38) in murine colorectal carcinoma through conjugation to poly (2-ethyl 2-oxazoline)-b-poly (L-glutamic acid) double hydrophilic copolymer.
Salmanpour M; Yousefi G; Samani SM; Mohammadi S; Anbardar MH; Tamaddon A
Eur J Pharm Sci; 2019 Aug; 136():104941. PubMed ID: 31136788
[TBL] [Abstract][Full Text] [Related]
13. ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies.
Amani N; Dorkoosh FA; Mobedi H
Curr Drug Deliv; 2020; 17(1):23-51. PubMed ID: 31755387
[TBL] [Abstract][Full Text] [Related]
14. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
[TBL] [Abstract][Full Text] [Related]
15. Custom-Designed Affinity Capture LC-MS F(ab')2 Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates.
Su D; Ng C; Khosraviani M; Yu SF; Cosino E; Kaur S; Xu K
Anal Chem; 2016 Dec; 88(23):11340-11346. PubMed ID: 27779866
[TBL] [Abstract][Full Text] [Related]
16. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
Zhang L; Fang Y; Kopeček J; Yang J
Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
[TBL] [Abstract][Full Text] [Related]
17. Complete regression of xenograft tumors using biodegradable mPEG-PLA-SN38 block copolymer micelles.
Lu L; Zheng Y; Weng S; Zhu W; Chen J; Zhang X; Lee RJ; Yu B; Jia H; Qin L
Colloids Surf B Biointerfaces; 2016 Jun; 142():417-423. PubMed ID: 26994941
[TBL] [Abstract][Full Text] [Related]
18. Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site.
Kumar A; Mao S; Dimasi N; Gao C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961794
[TBL] [Abstract][Full Text] [Related]
19. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
20. Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.
VanBrunt MP; Shanebeck K; Caldwell Z; Johnson J; Thompson P; Martin T; Dong H; Li G; Xu H; D'Hooge F; Masterson L; Bariola P; Tiberghien A; Ezeadi E; Williams DG; Hartley JA; Howard PW; Grabstein KH; Bowen MA; Marelli M
Bioconjug Chem; 2015 Nov; 26(11):2249-60. PubMed ID: 26332743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
